Jump to content

ADB-PINACA

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by EdChem (talk | contribs) at 08:24, 2 August 2016 (chem fixes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ADB-PINACA
Legal status
Legal status
Identifiers
  • N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H28N4O2
Molar mass344.51 g/mol g·mol−1
3D model (JSmol)
  • CCCCCN1C2=CC=CC=C2C(=N1)C(=O)NC(C(=O)N)C(C)(C)C
  • InChI=1S/C19H28N4O2/c1-5-6-9-12-23-14-11-8-7-10-13(14)15(22-23)18(25)21-16(17(20)24)19(2,3)4/h7-8,10-11,16H,5-6,9,12H2,1-4H3,(H2,20,24)(H,21,25)
  • Key:FWTARAXQGJRQKN-UHFFFAOYSA-N

ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively.[1][2] Like MDMB-FUBINACA, this compound contains an amino acid residue of tert-leucine.

Side effects

ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use.[3][4][5]

Legality

ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[6]

In the United States, it is a Schedule I controlled substance.[7]

As of October 2015 ADB-PINACA is a controlled substance in China.[8]

See also

References

  1. ^ Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alxendra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience. 6: 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
  2. ^ "ADB-PINACA". Forendex.
  3. ^ "CDC: 221 sickened by synthetic pot in Colorado". USA Today. December 12, 2013.
  4. ^ Michael D. Schwartz; et al. (March 2015). "A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA". Journal of Emergency Medicine. 48 (5): 573–580. doi:10.1016/j.jemermed.2014.12.038. PMID 25726258.
  5. ^ Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
  6. ^ "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 24 July 2015.
  7. ^ "Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order". Fed Regist. 79 (27): 7577–7582. Feb 10, 2014. PMID 24605391.
  8. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=ADB-PINACA&oldid=732640872"